Replimune (REPL) Shares Rebound Despite FDA Setback

 Replimune shares rebound after FDA setback on melanoma drug application. Analyst downgrades point to uncertainty and financial challenges ahead.

https://www.gurufocus.com/news/2998252/replimune-repl-shares-rebound-despite-fda-setback